Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protalix BioTherapeuticsFRA:PBDA +2.15%56 Median PS Value is €1.69 as of Aug. 19, 2026, which is 100% below its 10-year median of 1.27. GuruFocus rates FRA:PBDA with a GF Score™ of 56/100 and a GF Value™ of €1.89 (Fairly Valued). The stock has 4 warning signs investors should review. Among 278 Biotechnology companies, Protalix BioTherapeutics ranks worse than 79.86% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Protalix BioTherapeutics (FRA:PBDA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Protalix BioTherapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.00
/
1.69
=
1.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics Median PS Value Related Terms
Protalix BioTherapeutics Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PBDA vs GLSI, DTIL, NERV: Median PS Value Comparison
For the Biotechnology subindustry, Protalix BioTherapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.9953.
Protalix BioTherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.847.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (FRA:PBDA) has a Median PS Value of €1.69 as of Aug. 19, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Protalix BioTherapeutics and its competitors. This is 33% above median its historical median of 1.27. Over the past decade, Protalix BioTherapeutics' Median PS Value has ranged from 1.15 to 1.56. According to the industry distribution chart, Protalix BioTherapeutics ranks #222 out of 278 companies in the Biotechnology industry, placing it in the top 79.9%.
Is Protalix BioTherapeutics' Median PS Value too high?
Protalix BioTherapeutics' current Median PS Value of €1.69 is 33% above median its 10-year median of 1.27. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 1.56. Based on the distribution chart, Protalix BioTherapeutics ranks #222 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Protalix BioTherapeutics has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Median PS Value compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #222 out of 278 companies for Median PS Value. This places Protalix BioTherapeutics in the lower half of its industry. The industry median Median PS Value is 0.62. Historically, Protalix BioTherapeutics' own Median PS Value has ranged from 1.15 to 1.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Protalix BioTherapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current Median PS Value is €1.69, which is 33% above median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (FRA:PBDA) is currently considered Fairly Valued. The stock's GF Value™ is €1.89, compared to a current price of €2.00 — trading 5.8% above its estimated fair value. The current Median PS Value is €1.69, which is 33% above median its 10-year median of 1.27. Protalix BioTherapeutics' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Protalix BioTherapeutics (FRA:PBDA), the current Median PS Value is €1.69 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (FRA:PBDA) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of €2.00 is trading 5.8% above its estimated GF Value™ of €1.89.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for FRA:PBDA:
Median PS Value: €1.69 (33% above median its 10-year median of 1.27)
GF Value™: €1.89 vs. price of €2.00 (5.8% above fair value)
No single metric tells the full story. See the FRA:PBDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
56GF Score
Get the complete analysis for FRA:PBDA
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PBDA has been successfully added to your 
